Francis deSouza, Illumina CEO (Stefan Wermuth/Bloomberg via Getty Images)

As show­down with ac­tivist nears, Il­lu­mi­na’s CEO de­fends the com­pa­ny’s $7.1B pur­chase of Grail

Two years af­ter Il­lu­mi­na bought the can­cer test­ing com­pa­ny Grail, the DNA se­quenc­ing gi­ant re­mains be­lea­guered by an­titrust is­sues and is weeks away from the re­sults of a proxy fight that will de­ter­mine its fu­ture.

De­spite the pres­sures on Il­lu­mi­na and calls for his job by ac­tivist in­vestor Carl Ic­ahn, CEO Fran­cis deS­ouza in an in­ter­view with End­points News de­fend­ed the $7.1 bil­lion ac­qui­si­tion in 2021 as crit­i­cal to Il­lu­mi­na’s growth, and the quick­est path for scal­ing Grail’s ear­ly-de­tec­tion tests to reach more peo­ple.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.